Protagonist Therapeutics Inc
Protagonist Therapeutics develops oral peptide-based therapies for treating autoimmune and inflammatory diseases.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Protagonist Therapeutics' stock, believing it has good potential for growth.
Financial Health
Protagonist Therapeutics is performing well with strong revenue and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PTGX
The Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: August 19, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketNew Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Milestones
Clinical data and regulatory updates can rapidly change prospects, offering potential upside — though results are uncertain and setbacks are possible.
Clinical Reach
Programmes target gastrointestinal and immune conditions with substantial patient need, but commercial success depends on approvals and market access.
Innovation and Risk
Peptide-based approaches may offer novel therapies, yet they come with high R&D costs and binary trial outcomes; consider this if you seek higher-risk exposure.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
